A5050956429- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Muscle and Compartmental Disorders
- Blood transfusion and management
- Immunodeficiency and Autoimmune Disorders
- Protein Degradation and Inhibitors
- Hematological disorders and diagnostics
- Childhood Cancer Survivors' Quality of Life
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood groups and transfusion
- Cancer Genomics and Diagnostics
- Viral-associated cancers and disorders
- Chronic Myeloid Leukemia Treatments
- Chemotherapy-related skin toxicity
- Lung Cancer Treatments and Mutations
- Cancer Risks and Factors
- Chronic Lymphocytic Leukemia Research
Australian Red Cross Lifeblood
2025
Royal Darwin Hospital
2021-2024
Royal College of Pathologists of Australasia
2024
Canberra Hospital
2022
ACT Government
2022
PURPOSE A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS Patients either MRD (≥1 log 10 rise) relapse (blasts 5%-15%) received 600 mg once daily D1-28 plus LDAC D1-10 28-day cycles. The primary objective was response cohort complete remission (CR/CRh/CRi) cohort. RESULTS Forty-eight adults (n = 26) 22) were enrolled. Median age 67 years...
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic management algorithms have occurred within last decade. The availability of next-generation sequencing measurable residual disease assessment by flow cytometry allow for advanced prognostication response assessments. Novel therapies, including inhibitors Bruton's tyrosine kinase (BTKi) B-cell lymphoma 2 (BCL2) inhibitors, transformed...
Abstract Marginal zone lymphomas (MZLs) are a rare, indolent group of non‐Hodgkin with different diagnostic, genetic and clinical features therapeutic implications. The most common is extranodal MZL mucosa‐associated lymphoid tissue, followed by splenic nodal MZL. Patients generally have good outcomes long survival rates but frequently relapsing/remitting course requiring several lines therapy. heterogeneous presentation relapsing present the clinician diagnostic challenges. This position...
Haemopoietic stem cell transplant (HSCT) is a well-established treatment option for many haematologic immunologic and oncologic diseases, allowing the safe administration of high-dose chemotherapy. Increased risk acute renal injury associated with HSCT; however, chronic kidney in autologous HSCT remains unclear.This cohort study investigates incidence its predisposing factors single-centre population 139 patients who underwent HSCT.Estimated glomerular filtration rate (eGFR) was measured at...